CD8A and cancer: Research-grade TENDU constructs (LUR1-6) were tested in patient blood in the ex vivo blood loop assay pre and post a TTD-containing vaccination to determine if CD8+ or CD4+ T cell recall responses can be induced against the cancer epitopes in TENDU.